Ελβετία - Γερμανικά - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - hydroxycarbamidum - comprimés filmés sécables - hydroxycarbamidum 100 mg, cellulosum microcristallinum silicificatum, natrii stearylis fumaras, pellicule: copolymerum methacrylatis butylati basicum, pro compresso obducto, natrium 0.02 mg. - prévention des crises vaso-occlusives douloureuses récurrentes y compris celle du syndrome thoracique aigu chez l’adulte, l’adolescent et l'enfant âgé de plus de 2 ans souffrant de drépanocytose symptomatique - synthetika

Ελβετία - Γερμανικά - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - hydroxycarbamidum - comprimés filmés sécables - hydroxycarbamidum 1000 mg, cellulosum microcristallinum silicificatum, natrii stearylis fumaras, pellicule: copolymerum methacrylatis butylati basicum, pro compresso obducto, natrium 0.21 mg. - prévention des crises vaso-occlusives douloureuses récurrentes y compris celle du syndrome thoracique aigu chez l’adulte, l’adolescent et l'enfant âgé de plus de 2 ans souffrant de drépanocytose symptomatique - synthetika

Ελβετία - Γερμανικά - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - niraparibum, abirateroni acetas - filmtabletten - niraparibum 50 mg ut niraparibi tosilas monohydricus 79.7 mg, abirateroni acetas 500 mg corresp. abirateronum 446 mg, hypromellosum, natrii laurilsulfas, lactosum 240.54 mg ut lactosum monohydricum, crospovidonum, cellulosum microcristallinum silicificatum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, glyceroli monocaprylocapras, talcum, natrii laurilsulfas, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 5.05 mg. - prostatakarzinom - synthetika

Ελβετία - Γερμανικά - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - niraparibum, abirateroni acetas - filmtabletten - niraparibum 100 mg ut niraparibi tosilas monohydricus 159.4 mg, abirateroni acetas 500 mg corresp. abirateronum 446 mg, hypromellosum, natrii laurilsulfas, lactosum 240.54 mg ut lactosum monohydricum 253.2 mg, crospovidonum, cellulosum microcristallinum silicificatum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, glyceroli monocaprylocapras, talcum, natrii laurilsulfas, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 5.06 mg. - prostatakarzinom - synthetika

Ελβετία - Γερμανικά - Swissmedic (Swiss Agency for Therapeutic Products)

jazz pharmaceuticals switzerland gmbh - crisantaspasum - injektionslösung - crisantaspasum 10 mg, trehalosum dihydricum, natrii chloridum, dinatrii phosphas, dinatrii phosphas monohydricus, polysorbatum 80, natrii hydroxidum, aqua ad iniectabile, ad solutionem pro 0.5 ml corresp. natrium ca. 1 mg. - akute lymphatische leukämie (all), lymphoblastisches lymphom (lbl) - biotechnologika

Γερμανία - Γερμανικά - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sun pharmaceuticals germany gmbh (8127792) - carboplatin - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; carboplatin (23168) 10 milligramm

Ευρωπαϊκή Ένωση - Γερμανικά - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymphom, mantelzell - antineoplastische mittel - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Ευρωπαϊκή Ένωση - Γερμανικά - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukämie, haarige zelle - antineoplastische mittel - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Αυστρία - Γερμανικά - AGES (Agentur für Gesundheit und Ernährungssicherheit)

arcana arzneimittel gmbh - bortezomib -

Αυστρία - Γερμανικά - AGES (Agentur für Gesundheit und Ernährungssicherheit)

arcana arzneimittel gmbh - bortezomib -